ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Delivery

Novo Nordisk to buy drug delivery firm Emisphere

by Michael McCoy
November 14, 2020 | APPEARED IN VOLUME 98, ISSUE 44

 

09844-buscon15-pills.jpg
Credit: Novo Nordisk
Novo Nordisk uses Emisphere's Eligen technology to create an oral form of the diabetes drug semaglutide.

Novo Nordisk will pay $1.8 billion to acquire Emisphere Technology, a US firm with technology for creating oral versions of biologic drugs that otherwise would have to be injected. Novo licenses the technology to formulate semaglutide, a diabetes drug it sells as Rybelsus. Emisphere’s technology is based on carriers, such as salcaprozate sodium, that enhance absorption of both small and large molecules.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment